imu-131
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02795988)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- imu-131
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05311176 | Phase 2 | Aug 17, 2022 | Imugene Limited |
| NCT02795988 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Imugene Limited, Medical University of Vienna |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imugene Limited | For profit | 2 | 2 | 1 | 2016 |
| Medical University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1